Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06239194 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Head and Neck Cancer, sponsored by ModeX Therapeutics, An OPKO Health Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 6
- Study locations
NCT06239194: Recruiting Phase 1 study of Breast Cancer and Head and Neck Cancer, sponsored by ModeX Therapeutics, An OPKO Health Company.
NCT06239194 is a Phase 1 study of Breast Cancer and Head and Neck Cancer that is actively recruiting participants, run by ModeX Therapeutics, An OPKO Health Company. The registered enrollment target is 115 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06239194, a Phase 1 study of Breast Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by ModeX Therapeutics, An OPKO Health Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Primary Outcome
Incidence and severity of AEs and serious AEs (SAEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 including changes in clinical laboratory parameters
Conditions Studied
Interventions
- DRUG MDX2001
Study Locations (6)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Sylvester Comprehensive Cancer Center - University of Miami Health System - Miami
Massachusetts
- Massachusetts General Hospital - Boston
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT06239194 shows while recruiting
NCT06239194 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MDX2001 is the first listed.
NCT06239194 lists 6 locations in 5 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06239194 about?
NCT06239194 is a clinical study titled "Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors". This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
What is the current status of trial NCT06239194?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-06-12. Estimated completion is 2029-02.
What conditions does trial NCT06239194 study?
This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer, Endometrial Cancer, Gastric Cancer, Cervical Cancer.
What interventions are being tested in trial NCT06239194?
The interventions under investigation include: MDX2001 (DRUG).
Who is sponsoring clinical trial NCT06239194?
This trial is sponsored by ModeX Therapeutics, An OPKO Health Company, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06239194 being conducted?
This trial has 6 study locations across Colorado, Florida, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06239194's enrollment target sits among peer trials
115 523rd of 1224 higher than 697 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI